<DOC>
	<DOCNO>NCT00566228</DOCNO>
	<brief_summary>RATIONALE : It yet know method stem cell collection best patient undergo autologous stem cell transplant . PURPOSE : This randomized phase III trial compare two different method collect stem cell patient undergo stem cell transplant diffuse large cell lymphoma .</brief_summary>
	<brief_title>Two Different Methods Collecting Stem Cells For Autologous Stem Cell Transplant Treating Patients With Diffuse Large Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine therapeutic effect instrument-driven lymphocyte enrichment autograft absolute lymphocyte count ( A-ALC ) compare `` standard autograft collection '' determine progression-free survival post-transplantation . Secondary - Determine profile immune effector cell `` lymphocyte enrich autograft '' v `` standard autograft '' peripheral blood autologous stem cell transplant ( ASCT ) impact post- ASCT immunological reconstitution clinical endpoint . - Perform quantitative functional analysis T , B , NK , dendritic cell apheresis product peripheral blood sample multiple timepoints transplantation . - Determine compare proportion patient progression-free alive 1 2 year . - Determine difference overall survival two collection method arm . - Evaluate characterize difference transplantation outcome ( e.g. , time ALC engraftment , incidence infection , CD34 count ) two collection method arm . OUTLINE : Patients stratify accord baseline International Prognostic Factor ( ≥ 2 factor vs &lt; 2 factor ) PET scan finding prior transplantation ( positive v negative ) . Patients receive filgrastim ( G-CSF ) alone G-CSF sargramostim ( GM-CSF ) daily stem cell mobilization . Once peripheral CD34-positive cell count reach ≥ 10/μL , patient undergo stem cell collection . Patients randomize 1 2 treatment arm standard autologous stem cell transplantation ( ASCT ) . - Immunologic autograft engineering : Patients ' stem cell collect accord modified Amicus setting ( i.e. , MNC OFFSET = 0.0 RBC = 7.0 ) . Patients undergo ASCT IV day apheresis ( lymphocyte enrich autograft ) . - Standard autograft collection : Patients ' stem cell collect accord standard Amicus setting ( i.e. , MNC OFFSET = 1.5 RBC OFFSET = 5.0 ) . Patients undergo ASCT IV day apheresis . Patients undergo blood sample collection periodically immunological study . Samples analyze immunophenotyping immune cell subset via multicolor flow cytometry , immunoglobulin reconstitution , functional T-cell immunity . After completion study treatment , patient follow day 15 post ASCT 3 , 6 , 9 , 12 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis diffuse large cell lymphoma Lowgrade nonHodgkin lymphoma transform diffuse large cell lymphoma allow Candidate autologous peripheral blood stem cell transplantation Not require bone marrow harvest collect stem cell No chemotherapy filgrastim ( GCSF ) mobilization study drug ( i.e. , AMD3100 ) need mobilization stem cell PATIENT CHARACTERISTICS : ECOG performance status 01 Cardiac pulmonary status sufficient undergo apheresis stem cell transplantation Negative pregnancy test Not pregnant nursing Fertile patient must use effective contraception HIV negative No active uncontrolled infection require antibiotic treatment No comorbid condition , view investigator , render patient high risk treatment complication Willing provide research blood sample require protocol PRIOR CONCURRENT THERAPY : At least 4 week since prior chemotherapy ( rituxan consider chemotherapy purpose study ) More 4 week since prior experimental therapy No concurrent enrollment another experimental protocol mobilization phase No concurrent participation autologous stem cell transplantation study use standard conditioning regimen lymphomas</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
</DOC>